BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

232 related articles for article (PubMed ID: 29719017)

  • 1. Cutaneous CD30-positive T-cell lymphoproliferative disorders-clinical and histopathologic features, differential diagnosis, and treatment.
    Kempf W; Kerl K; Mitteldorf C
    Semin Cutan Med Surg; 2018 Mar; 37(1):24-29. PubMed ID: 29719017
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A new era for cutaneous CD30-positive T-cell lymphoproliferative disorders.
    Kempf W
    Semin Diagn Pathol; 2017 Jan; 34(1):22-35. PubMed ID: 27993440
    [TBL] [Abstract][Full Text] [Related]  

  • 3. CD30-Positive Lymphoproliferative Disorders.
    Nikolaenko L; Zain J; Rosen ST; Querfeld C
    Cancer Treat Res; 2019; 176():249-268. PubMed ID: 30596222
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Primary Cutaneous CD30+ Lymphoproliferative Disorders: a Comprehensive Review.
    Di Raimondo C; Parekh V; Song JY; Rosen ST; Querfeld C; Zain J; Martinez XU; Abdulla FR
    Curr Hematol Malig Rep; 2020 Aug; 15(4):333-342. PubMed ID: 32435988
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Primary cutaneous CD30+ lymphoproliferative disorders: new insights into biology and therapy.
    Querfeld C; Kuzel TM; Guitart J; Rosen ST
    Oncology (Williston Park); 2007 May; 21(6):689-96; discussion 699-700,. PubMed ID: 17564326
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Contribution of longitudinal follow up and clinical pathological correlation in the diagnosis CD30-positive skin infiltrates.
    De Souza A; Carter JB; Harris NL; Ferry JA; Duncan LM
    J Cutan Pathol; 2015 Jul; 42(7):452-8. PubMed ID: 25931140
    [TBL] [Abstract][Full Text] [Related]  

  • 7. CD30-positive lymphoproliferative disorders-An Australian Clinical Practice Statement from the Peter MacCallum Cancer Centre.
    Bhabha FK; McCormack C; Campbell BA; Lade S; Buelens O; Van Der Weyden C; Prince HM
    Australas J Dermatol; 2023 May; 64(2):194-203. PubMed ID: 36892928
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The t(2;5) chromosomal translocation is not a common feature of primary cutaneous CD30+ lymphoproliferative disorders: comparison with anaplastic large-cell lymphoma of nodal origin.
    DeCoteau JF; Butmarc JR; Kinney MC; Kadin ME
    Blood; 1996 Apr; 87(8):3437-41. PubMed ID: 8605362
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Primary cutaneous CD30+ lymphoproliferative disorder--a 10-year follow-up. A case report and differential diagnosis.
    Szpor J; Dyduch G; Gałazka K; Bahyrycz J; Stój A; Tomaszewska R
    Pol J Pathol; 2009; 60(1):43-8. PubMed ID: 19670703
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The spectrum of CD30+ T cell lymphoproliferative disorders in the skin.
    Kartan S; Johnson WT; Sokol K; Alpdogan O; Gru AA; Nikbakht N; Porcu P
    Chin Clin Oncol; 2019 Feb; 8(1):3. PubMed ID: 30691273
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Practical Management of CD30⁺ Lymphoproliferative Disorders.
    Hughey LC
    Dermatol Clin; 2015 Oct; 33(4):819-33. PubMed ID: 26433852
    [TBL] [Abstract][Full Text] [Related]  

  • 12. MUM1 expression in cutaneous CD30+ lymphoproliferative disorders: a valuable tool for the distinction between lymphomatoid papulosis and primary cutaneous anaplastic large-cell lymphoma.
    Kempf W; Kutzner H; Cozzio A; Sander CA; Pfaltz MC; Müller B; Pfaltz M
    Br J Dermatol; 2008 Jun; 158(6):1280-7. PubMed ID: 18410414
    [TBL] [Abstract][Full Text] [Related]  

  • 13. EORTC, ISCL, and USCLC consensus recommendations for the treatment of primary cutaneous CD30-positive lymphoproliferative disorders: lymphomatoid papulosis and primary cutaneous anaplastic large-cell lymphoma.
    Kempf W; Pfaltz K; Vermeer MH; Cozzio A; Ortiz-Romero PL; Bagot M; Olsen E; Kim YH; Dummer R; Pimpinelli N; Whittaker S; Hodak E; Cerroni L; Berti E; Horwitz S; Prince HM; Guitart J; Estrach T; Sanches JA; Duvic M; Ranki A; Dreno B; Ostheeren-Michaelis S; Knobler R; Wood G; Willemze R
    Blood; 2011 Oct; 118(15):4024-35. PubMed ID: 21841159
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Is immunohistochemical expression of GATA3 helpful in the differential diagnosis of transformed mycosis fungoides and primary cutaneous CD30-positive T cell lymphoproliferative disorders?
    Collins K; Gu J; Aung PP; Nagarajan P; Curry JL; Huen A; Ivan D; Prieto VG; Tetzlaff MT; Duvic M; Miranda RN; Vega F; Torres-Cabala CA
    Virchows Arch; 2021 Aug; 479(2):377-383. PubMed ID: 33604757
    [TBL] [Abstract][Full Text] [Related]  

  • 15. SATB1 Defines a Subtype of Cutaneous CD30
    Sun J; Yi S; Qiu L; Fu W; Wang A; Liu F; Wang L; Wang T; Chen H; Wang L; Kadin ME; Tu P; Wang Y
    J Invest Dermatol; 2018 Aug; 138(8):1795-1804. PubMed ID: 29510190
    [TBL] [Abstract][Full Text] [Related]  

  • 16. CD30/Ki-1-positive lymphoproliferative disorders of the skin--clinicopathologic correlation and statistical analysis of 86 cases: a multicentric study from the European Organization for Research and Treatment of Cancer Cutaneous Lymphoma Project Group.
    Paulli M; Berti E; Rosso R; Boveri E; Kindl S; Klersy C; Lazzarino M; Borroni G; Menestrina F; Santucci M
    J Clin Oncol; 1995 Jun; 13(6):1343-54. PubMed ID: 7751878
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Primary cutaneous CD30(+) lymphoproliferative disorders.
    Wieser I; Tetzlaff MT; Torres Cabala CA; Duvic M
    J Dtsch Dermatol Ges; 2016 Aug; 14(8):767-82. PubMed ID: 27509411
    [TBL] [Abstract][Full Text] [Related]  

  • 18. CD30-positive lymphoproliferative disorders arising after regional therapy for recurrent melanoma: a report of two cases and analysis of CD30 expression.
    Gill K; Ariyan C; Wang X; Brady MS; Pulitzer M
    J Surg Oncol; 2014 Sep; 110(3):258-64. PubMed ID: 24891295
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinicopathologic and microenvironmental analysis of primary cutaneous CD30-positive lymphoproliferative disorders: a 26 year experience from an academic medical center in Brazil.
    Ferreira CR; Zhao S; Sanches JA; Miyashiro D; Cury-Martins J; Azevedo RS; Zerbini MCN; Natkunam Y; Gratzinger D
    Diagn Pathol; 2019 Oct; 14(1):115. PubMed ID: 31640798
    [TBL] [Abstract][Full Text] [Related]  

  • 20. CD30+ cutaneous lymphoproliferative disorders: the Stanford experience in lymphomatoid papulosis and primary cutaneous anaplastic large cell lymphoma.
    Liu HL; Hoppe RT; Kohler S; Harvell JD; Reddy S; Kim YH
    J Am Acad Dermatol; 2003 Dec; 49(6):1049-58. PubMed ID: 14639383
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.